Employees: 1,195
Size Dezhan Healthcare (000813.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $825M, the 2525th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.66 on 18 Nov 2026.
Performance Over six months the shares fell 32.8%, against -7.9% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth Revenue fell 10.3% over the last twelve months (peer median +7.7%); the operating margin is -120.8% (peer median 10.0%).
Valuation It trades at 13.8× enterprise value to sales against a peer median of 2.9× (3rd most expensive of 17).
Capital Return on invested capital runs 14.7 points below its cost of capital (8.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥349M | CN¥393M | CN¥463M | CN¥487M | CN¥561M |
| Revenue growth | — | -15% | -5% | -13% | — |
| Gross profit | CN¥215M | CN¥164M | CN¥246M | CN¥235M | CN¥259M |
| EBITDA | n/a | -CN¥129M | -CN¥510,070 | CN¥25.4M | -CN¥60.3M |
| Net income | -CN¥388M | -CN¥345M | -CN¥20.4M | CN¥83.3M | -CN¥47.0M |
| Free cash flow | -CN¥270M | -CN¥231M | -CN¥181M | -CN¥31.9M | CN¥127M |
| Capital expenditure | CN¥222M | CN¥236M | CN¥167M | CN¥160M | CN¥67.6M |
| Total debt | CN¥129M | CN¥135M | CN¥18.1M | CN¥7.57M | CN¥24.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000813.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.3% | -7.0% | 5th lowest of 20 |
| 6-month return | -32.8% | -7.9% | 4th lowest of 19 |
| Distance from 52-week high | -43.8% | -34.1% | 8th lowest of 20 |
| Revenue growth (TTM) | -10.3% | +7.7% | 3rd lowest of 18 |
| Operating margin | -120.8% | 10.0% | 4th lowest of 18 |
| EV / Sales | 13.8× | 2.9× | 3rd most expensive of 17 |
| ROIC minus cost of capital | -14.7 pp | -0.7 pp | 3rd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | 13.8× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | 6.5× | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | 7.0× | 27.7% | -39.5% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | 4.7× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 1.8× | 4.6% | +22.5% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | 789.4× | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 5.8× | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | 15.3× | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 0.9× | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |